DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN IN DEXTROSE 5%

« Back to Dashboard

505(b)(2) Clinical Trials for Ciprofloxacin In Dextrose 5%

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01168895	Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder	Completed	Bayer	Phase 1	2010-07-01	The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients. In this study the 48.75 mg dose will be administered for the first time using a new high dose strength (i.e. one capsule containing 75 mg powder = 48.75 mg ciprofloxacin) formulation. Safety investigations will focus on local tolerability in the lung and evaluate whether the patient can inhale the higher amount of powder compared to the lower dose strength. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. Results from this study will be used to decide whether the new dose strength is suitable for larger clinical trials planned for the COPD patients population.

All Clinical Trials for Ciprofloxacin In Dextrose 5%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000641	A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per 03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is the most common systemic bacterial infection complicating AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely poor, particularly when it follows other opportunistic infections or is associated with anemia. Test tube studies and clinical data indicate that the best treatment program may include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because it must be administered parenterally (by injection or intravenously).
NCT00002850	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Eastern Cooperative Oncology Group	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Gary Morrow	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.

Clinical Trial Conditions for Ciprofloxacin In Dextrose 5%

Condition Name

Condition Name for Ciprofloxacin In Dextrose 5%
Intervention	Trials
Healthy	11
Urinary Tract Infections	11
Infection	8
Cystic Fibrosis	7

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ciprofloxacin In Dextrose 5%
Intervention	Trials
Infection	33
Communicable Diseases	29
Urinary Tract Infections	21
Fibrosis	14

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ciprofloxacin In Dextrose 5%

Trials by Country

Trials by Country for Ciprofloxacin In Dextrose 5%
Location	Trials
United States	415
Germany	44
United Kingdom	37
Spain	34
Canada	34

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ciprofloxacin In Dextrose 5%
Location	Trials
Texas	26
California	25
Florida	23
North Carolina	21
Pennsylvania	19

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ciprofloxacin In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Ciprofloxacin In Dextrose 5%
Clinical Trial Phase	Trials
Phase 4	51
Phase 3	55
Phase 2/Phase 3	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ciprofloxacin In Dextrose 5%
Clinical Trial Phase	Trials
Completed	104
Recruiting	45
Not yet recruiting	30

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ciprofloxacin In Dextrose 5%

Sponsor Name

Sponsor Name for Ciprofloxacin In Dextrose 5%
Sponsor	Trials
Bayer	22
Novartis	6
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	6

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ciprofloxacin In Dextrose 5%
Sponsor	Trials
Other	234
Industry	120
NIH	15

Export unavailable in trial.
Subscribe for complete access.